Company intelligence / Profile preview

TEI Biosciences

Boston, Massachusetts, United States

Ownership: Private
Employees: ~19
Development stage: Other

Overview

TEI Biosciences developed and commercialized biologic devices based on acellular collagen matrices for soft tissue repair and regeneration. Their products, including SurgiMend and PriMatrix, were marketed and in clinical use before the company was acquired by Integra LifeSciences, enhancing Integra's regenerative wound care and tissue repair portfolio.

Therapeutic areas: Women's HealthOtherEndocrinologyNeurologyDermatologyGastroenterology
Modalities: BiologicDevice
Industry: Therapeutic Medical Devices

Partnerships

MedtronicBoston ScientificNovation

Beyond the preview

Go deeper on TEI Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEI Biosciences.

Explore the full profile